English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The treatment of migraine now includes the possibility of using the anti CGRP monoclonal antibodies erenumab, fremanezumab and galcanezumab. Registration studies and real life studies have shown excellent efficacy and extraordinary tolerability of these treatments. Little is known about the possible differences between the three treatments and this observational study was conducted with a view to comparing the efficacy, safety and impact that anti-CGRP monclonal antibodies have on additional parameters such as disability in social, family and work activities.

Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine